STOCK TITAN
  1. Home
  2. News
  3. BVS

Bioventus Inc. - BVS STOCK NEWS

Welcome to our dedicated page for Bioventus news (Ticker: BVS), a resource for investors and traders seeking the latest updates and insights on Bioventus stock.

Bioventus Inc. (Nasdaq: BVS) is a global leader in orthobiologics, committed to providing innovative solutions that enhance the body’s natural healing processes. The company offers a comprehensive array of medical technology products designed to support musculoskeletal healing, including orthobiologic treatments, surgical solutions, and pain management therapies.

Founded in 2012 and headquartered in Durham, North Carolina, Bioventus has grown to employ nearly 600 professionals worldwide, with international offices in Hoofddorp, the Netherlands; Memphis, Tennessee; Australia; Canada; and a research and development site in Boston. The company’s mission is to help patients resume and enjoy active lives by delivering clinically proven, cost-effective products that ensure quick and safe recovery.

Bioventus operates through two main product portfolios: Bioventus Active Healing Therapies and Bioventus Surgical. These portfolios are enhanced through internal product development, strategic acquisitions, and distribution agreements. Their diverse range of products spans various medical specialties, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery.

Financially, Bioventus has demonstrated resilience and growth, reporting in its latest quarterly results a robust increase in adjusted EBITDA and significant improvements in cash flow and operating income. Despite a slight dip in total net sales, the company saw strong volumes in Surgical Solutions and substantial growth in its international markets.

Recent highlights include management’s focused efforts to stabilize operations, enhance liquidity, and maintain spending discipline. This strategic approach has positioned Bioventus to accelerate revenue growth and create long-term value for its stakeholders. The company continues to be a trusted partner to physicians and healthcare providers globally, offering high-quality, evidence-based medical solutions.

News

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

Rhea-AI Summary
Bioventus Inc. (BVS) will announce Q4 fiscal year 2024 financial results on March 12, 2024. A conference call will be held to discuss the results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences earnings
-
News

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

Rhea-AI Summary
Bioventus Inc. (BVS) announced an Amendment to the Credit and Guaranty Agreement, providing financial covenant relief through the Third Quarter of 2025, allowing greater financial and operational flexibility for key growth initiatives and profitability enhancement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
none
-
News

Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

Rhea-AI Summary
Bioventus Inc. (Nasdaq: BVS) issued inducement equity awards to Robert Claypoole as President and CEO, consisting of 375,000 restricted share units and options to purchase 850,000 shares of the Company's Class A common stock. The awards will vest in four equal installments on the first four anniversaries of January 10, 2024, subject to continued employment. The exercise price for the options is $4.89. The awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.76%
Tags
none
News

Bioventus Names Robert Claypoole as President and Chief Executive Officer

Rhea-AI Summary
Bioventus Inc. (Nasdaq: BVS) appoints Robert Claypoole as President and CEO, bringing over 20 years of medical device industry experience. The company reaffirms its full year financial guidance and expresses excitement for the future under Claypoole's leadership.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.25%
Tags
none
-
News

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

Rhea-AI Summary
Bioventus Inc. (BVS) has secured a nationwide contract with Aetna™ Medicare Advantage plans, granting over 3 million members access to DUROLANE, a single-injection hyaluronic acid-based joint-fluid treatment for knee osteoarthritis (OA) pain, starting January 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
none
-
News

Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance

Rhea-AI Summary
Bioventus Inc. reported Q3 net sales of $120.8 million, down 6.1% year-over-year. The company's net loss from continuing operations was $8.8 million, compared to $101.0 million in the prior-year period. Adjusted EBITDA from continuing operations decreased 0.9%, and the loss per share of Class A common stock from continuing operations was $0.12. Pain Treatments revenue advanced 3.1%, and the company is raising its full-year earnings guidance. The company expects net sales of $498 million to $505 million and adjusted EBITDA of $84 million to $87 million for the twelve months ending December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
earnings
News

Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023

Rhea-AI Summary
Bioventus Inc. will report financial results for Q3 2023 on November 7, 2023. The conference call to discuss the results and provide a business update will be held at 8:30 a.m. Eastern Time. Dial 1-800-715-9871 or 1-646-307-1963 to participate. Webcast and materials will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.37%
Tags
conferences earnings
-
News

Bioventus to Present at the Cantor Global Healthcare Conference

Rhea-AI Summary
Bioventus CFO to participate in fireside chat at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences
-
News

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Rhea-AI Summary
Bioventus CEO to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.22%
Tags
conferences
News

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

Rhea-AI Summary
Bioventus Inc. reports Q2 net sales of $137.1 million, down 2.3% YoY. Adjusted EBITDA increases 26.1% to $28.2 million. Loss per share of Class A common stock decreases to $0.06. Non-GAAP earnings per share of Class A common stock increase to $0.14. Total net sales decline due to lower Pain Treatment pricing and Wound Business divestiture. Gross margin decreases to 65.0%. Operating income improves to $6.8 million. Net loss from continuing operations decreases to $4.7 million. Adjusted EBITDA increases to $28.2 million. Non-GAAP net income and earnings per share of Class A common stock increase to $10.9 million and $0.14, respectively. Company expects net sales of $490 million to $505 million for 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.12%
Tags
earnings

FAQ

What is the current stock price of Bioventus (BVS)?

The current stock price of Bioventus (BVS) is $12.28 as of December 2, 2024.

What is the market cap of Bioventus (BVS)?

The market cap of Bioventus (BVS) is approximately 805.3M.

What does Bioventus Inc. specialize in?

Bioventus Inc. specializes in orthobiologics, providing products for musculoskeletal healing, regeneration, and biosurgery that enhance the body's natural healing processes.

Where is Bioventus Inc. headquartered?

Bioventus Inc. is headquartered in Durham, North Carolina, with international offices in Hoofddorp, the Netherlands, and other locations worldwide.

What are the main product portfolios of Bioventus?

Bioventus operates through two main product portfolios: Bioventus Active Healing Therapies and Bioventus Surgical.

How does Bioventus improve its product offerings?

Bioventus enhances its product offerings through internal product development, strategic acquisitions, and distribution agreements.

What medical specialties does Bioventus cater to?

Bioventus caters to various medical specialties, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery.

What recent financial achievements has Bioventus made?

Bioventus recently reported significant growth in adjusted EBITDA, improved cash flow, and operating income, despite a slight decline in total net sales.

What is the mission of Bioventus?

The mission of Bioventus is to help patients resume and enjoy active lives by providing clinically proven, cost-effective products that ensure quick and safe recovery.

How does Bioventus contribute to patient care?

Bioventus contributes to patient care by offering innovative orthobiologic products that support musculoskeletal healing and enhance the body’s natural healing processes.

What are Bioventus’s strategic priorities?

Bioventus’s strategic priorities include stabilizing operations, enhancing liquidity, maintaining spending discipline, and accelerating revenue growth to create long-term value.

How is Bioventus positioned in the global market?

Bioventus is a trusted partner for physicians and healthcare providers worldwide, known for its high-quality, evidence-based medical solutions and commitment to ethical behavior.

Stock BVS logo
Bioventus Inc.

Nasdaq:BVS

BVS Rankings

#2764 Ranked by Market Cap
N/A Ranked by Dividends

BVS Stock Data

805.33M
57.83M
11.48%
69.82%
1.78%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
DURHAM